Product logins

Find logins to all Clarivate products below.


Eosinophilic Esophagitis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of EoE for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s EoE forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of EoE?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of EoE over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts five EoE patient populations, as follows:

  • Diagnosed prevalent cases
  • Diagnosed prevalent cases by phenotypes
  • Diagnosed prevalent cases with comorbid allergic rhinitis
  • Diagnosed prevalent cases with comorbid asthma
  • Diagnosed prevalent cases with comorbid atopic dermatitis

Related Market Assessment Reports

Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
Report
Crohn’s Disease – Access & Reimbursement – Access & Reimbursement – Crohn’s Disease (US)
TNF-α inhibitors, such as J&J Innovative Medicine’s Remicade and AbbVie’s Humira, remain firmly established in the U.S. Crohn’s disease (CD) treatment landscape. However, therapies with…
Report
Ulcerative Colitis – Current Treatment – Current Treatment: Physician Insights – Ulcerative Colitis (EU5)
Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha (J&J Innovative Medicine’s Remicade and AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…